Cargando…

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML

Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are chronic myeloid clonal neoplasms. To date, the only potentially curative therapy for these disorders remains allogeneic hematopoietic progenitor cell transplantation (HCT), although patient eligibility is limited due to h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banús-Mulet, Antònia, Etxabe, Amaia, Cornet-Masana, Josep Maria, Torrente, Miguel Ángel, Lara-Castillo, María Carmen, Palomo, Laura, Nomdedeu, Meritxell, Díaz-Beyá, Marina, Solé, Francesc, Nomdedeu, Benet, Esteve, Jordi, Risueño, Ruth M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141614/ https://www.ncbi.nlm.nih.gov/pubmed/30224768 http://dx.doi.org/10.1038/s41598-018-32306-4

Ejemplares similares

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma
por: Nomdedeu, Meritxell, et al.
Publicado: (2015)

Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells
por: Cornet-Masana, Josep Maria, et al.
Publicado: (2016)

XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells
por: Moreno-Martínez, Daniel, et al.
Publicado: (2014)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells
por: Cornet-Masana, Josep M., et al.
Publicado: (2019)

Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity
por: Cornet‐Masana, Josep M., et al.
Publicado: (2020)

Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia
por: Cuesta-Casanovas, Laia, et al.
Publicado: (2023)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia
por: Carbó, José M., et al.
Publicado: (2023)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature
por: Molina-Urra, Ricardo, et al.
Publicado: (2015)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature
por: Díaz-Beyá, Marina, et al.
Publicado: (2015)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
por: Garcia-Manero, G, et al.
Publicado: (2017)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia
por: Díaz-Beyá, M, et al.
Publicado: (2015)

Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
por: Guijarro, Francesca, et al.
Publicado: (2023)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Transformation of CMML to AML presenting with acute kidney injury
por: DeBoer, Rebecca, et al.
Publicado: (2020)

Wiring the senses: Factors that regulate peripheral axon pathfinding in sensory systems
por: Nomdedeu‐Sancho, Gemma, et al.
Publicado: (2022)

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
por: Kuendgen, A., et al.
Publicado: (2020)

Induced pluripotent stem cells as suitable sensors for fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome
por: Monzón-Nomdedeu, María B, et al.
Publicado: (2021)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Many signs, one mutation: Early onset of de novo GATA2 deficiency syndrome. A case report
por: Blanco, Maria Laura, et al.
Publicado: (2020)

A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML
por: Elghazaly, Assem A., et al.
Publicado: (2016)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

TET2 missense variants in human neoplasia. A proposal of structural and functional classification
por: Bussaglia, Elena, et al.
Publicado: (2019)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Lysosome-mediated chemoresistance in acute myeloid leukemia
por: Cuesta-Casanovas, Laia, et al.
Publicado: (2022)

Constitutionally High Serotonin Tone Favors Obesity: Study on Rat Sublines With Altered Serotonin Homeostasis
por: Kesić, Maja, et al.
Publicado: (2020)

Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report
por: Hu, Lianbo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_278p7dor60i3khhe3p86i4pk9n